肝硬化患者肝性脑病后的结局:基于人群的队列研究
结果显示肝性脑病仍伴随高病死率和再入院率,胃肠科会诊及乳果糖联合利福昔明与更好结局相关。
要点
- ≥65岁患者肝性脑病后中位生存仅0.95年,<65岁为2.5年。
- 胃肠科会诊和利福昔明使用与较低死亡风险相关。
- 乳果糖联合利福昔明与最少住院天数相关。
核心结论
- 肝性脑病在当代肝硬化患者中仍伴随高病死率和医疗利用,胃肠科会诊及乳果糖联合利福昔明与改善结局相关。
主要发现
- 肝性脑病后中位生存:≥65岁为0.95年,<65岁为2.5年;有腹水者为1.1年,无腹水者为3.9年。
- 非酒精性脂肪性肝病在病因中调整后死亡风险最高,HR 1.07(95%CI 1.02-1.12)。
- 胃肠科会诊调整后HR 0.73(95%CI 0.67-0.80),利福昔明调整后HR 0.40(95%CI 0.39-0.42)。
- 30天再入院率:胃肠科会诊0.71(95%CI 0.57-0.88),利福昔明0.18(95%CI 0.08-0.40)。
- 住院天数发生率比:单用乳果糖0.31(95%CI 0.30-0.32),单用利福昔明0.49(95%CI 0.45-0.53),联合治疗0.28(95%CI 0.27-0.30)。
临床怎么用
- 对肝硬化肝性脑病患者,应考虑胃肠科会诊并评估乳果糖联合利福昔明治疗以改善结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Hepatic encephalopathy is a devastating complication of cirrhosis. AIM: To describe the outcomes after developing hepatic encephalopathy among contemporary, aging patients. METHODS: We examined data for a 20% random sample of United States Medicare enrolees with cirrhosis and Part D prescription coverage from 2008 to 2014. Among 49 164 persons with hepatic encephalopathy, we evaluated the associations with transplant-free survival using Cox proportional hazard models with time-varying covariates (hazard ratios, HR) and incidence rate ratios (IRR) for healthcare utilisation measured in hospital-days and 30-day readmissions per person-year. We validated our findings in an external cohort of 2184 privately insured patients with complete laboratory values. RESULTS: Hepatic encephalopathy was associated with median survivals of 0.95 and 2.5 years for those ≥65 or <65 years old and 1.1 versus 3.9 years for those with and without ascites. Non-alcoholic fatty-liver disease posed the highest adjusted risk of death among aetiologies, HR 1.07 95% CI (1.02, 1.12). Both gastroenterology consultation and rifaximin utilisation were associated with lower mortality, respective adjusted-HR 0.73 95% CI (0.67, 0.80) and 0.40 95% CI (0.39, 0.42). Thirty-day readmissions were fewer for patients seen by gastroenterologists (0.71 95% CI [0.57-0.88]) and taking rifaximin (0.18 95% CI [0.08-0.40]). Lactulose alone was associated with fewer hospital-days, IRR 0.31 95% CI (0.30-0.32), than rifaximin alone, 0.49 95% CI (0.45-0.53), but the optimal therapy combination was lactulose/rifaximin, IRR 0.28 95% CI (0.27-0.30). These findings were validated in the privately insured cohort adjusting for model for endstage liver disease-sodium score and serum albumin. CONCLUSIONS: Hepatic encephalopathy remains morbid and associated with poor outcomes among contemporary patients. Gastroenterology consultation and combination lactulose-rifaximin are both associated with improved outcomes. These data inform the development of care coordination efforts for subjects with cirrhosis.
引用
- Tapper EB, Aberasturi D, Zhao Z, et al. Outcomes after hepatic encephalopathy in population-based cohorts of patients with cirrhosis. Aliment Pharmacol Ther. 2020. PMID: 32363684. doi:10.1111/apt.15749
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。